NEW YORK, April 5, 2018 /PRNewswire/ —
Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration company, announced today that Denis Corin, Chief Executive Officer, will present at the MicroCap Conference being held at the Essex House in New York City, on Tuesday April 9th and 10th, 2018. In addition to presenting, Mr. Corin will be available for one-on-one investor meetings on Tuesday the 10th.
Details of Q BioMed’s’ participation are as follows:
Event: The Microcap Conference Date: Tuesday April 10th, 2018 Time: 12:00 p.m. Eastern Time Location: Essex House - 160 Central Park South, New York, NY
The MicroCap Conference is an exclusive event dedicated to connecting small and micro-cap companies with high-level, institutional and retail investors.
This seventh Microcap Conference is being held at the luxurious Essex House overlooking Central Park. The MicroCap Conference will highlight the 120 of the most attractive companies across various sectors.
About Q BioMed Inc.
Q BioMed, Inc. is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support and expansion capital they need to meet their developmental potential so that they can provide products to patients in need.
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Q BioMed Inc.
SOURCE Q BioMed Inc.